Alirocumab after acute coronary syndrome in patients with a history of heart failure

AIMS: Patients with heart failure (HF) have not been shown to benefit from statins. In a post hoc analysis, we evaluated outcomes in ODYSSEY OUTCOMES in patients with vs. without a history of HF randomized to the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab or placebo....

Descripción completa

Detalles Bibliográficos
Autores principales: White, Harvey D, Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Diaz, Rafael, Goodman, Shaun G, Jukema, Johan Wouter, Loy, Megan, Pagidipati, Neha, Pordy, Robert, Ristić, Arsen D, Zeiher, Andreas M, Wojdyla, Daniel M, Steg, Philippe Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020985/
https://www.ncbi.nlm.nih.gov/pubmed/34922353
http://dx.doi.org/10.1093/eurheartj/ehab804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020985/
https://www.ncbi.nlm.nih.gov/pubmed/34922353
http://dx.doi.org/10.1093/eurheartj/ehab804

Ejemplares similares